Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.

Clinical and Vaccine Immunology : CVI
Jesús ArenasPeter van der Ley

Abstract

Wild-type lipopolysaccharide (LPS) of Neisseria meningitidis normally contains six acyl chains. Penta-acylated LPS forms were generated through inactivation of the lpxL1 gene or through the expression of the Bordetella bronchiseptica pagL gene in N. meningitidis. The resulting LPS species, designated LpxL1 LPS and PagL LPS, respectively, display reduced endotoxic activity compared to wild-type LPS. Here, we determined the adjuvant potential of PagL LPS by comparison with the broadly used LpxL1 LPS. We also investigated the potential benefit for adjuvanticity of coincorporating these LPS species, together with the meningococcal opacity-associated protein OpaJ as a model antigen, in a liposomal delivery system. PagL LPS showed a higher endotoxic activity than LpxL1 LPS, and their incorporation into liposomes significantly reduced their endotoxic activity as determined by measuring the induction of interleukin-6 (IL-6) production in a murine macrophage cell line. To determine the adjuvant effect, BALB/c mice were immunized with OpaJ-containing liposomes and either free LPS or LPS coincorporated into the proteoliposomes. OpaJ-containing liposomes adjuvanted with AlPO(4) or not adjuvanted at all were included as control groups. In t...Continue Reading

References

Dec 1, 1990·Journal of Clinical Microbiology·A FomsgaardC Galanos
Jun 1, 1985·Infection and Immunity·J V Desiderio, S G Campbell
Jan 1, 1989·Critical Reviews in Microbiology·H Takada, S Kotani
Apr 1, 1989·The Journal of Infectious Diseases·T F PattersonV T Andriole
Apr 21, 1998·Nature·L SteeghsP van der Ley
Sep 1, 2000·International Journal of Pharmaceutics·N Venkatesan, S P Vyas
Dec 26, 2001·FEMS Immunology and Medical Microbiology·R D WeeratnaH L Davis
Oct 24, 2002·European Journal of Biochemistry·Marien I de JongePeter van der Ley
Dec 11, 2003·Microbiology and Molecular Biology Reviews : MMBR·Hiroshi Nikaido
Jan 27, 2004·Vaccine·Carmen ArigitaGideon F A Kersten
Sep 24, 2004·Immunology·Eva M Pålsson-McDermott, Luke A J O'Neill
Feb 24, 2007·Nature Reviews. Immunology·Giorgio Trinchieri, Alan Sher
Oct 13, 2007·Expert Review of Vaccines·Manmohan SinghDerek O'Hagan

❮ Previous
Next ❯

Citations

Mar 24, 2015·Expert Review of Vaccines·Afshin Zariri, Peter van der Ley
Mar 29, 2014·Current Opinion in Biotechnology·Jenny L BakerMatthew P DeLisa
Jul 26, 2014·Environmental Microbiology·Jesús ArenasJan Tommassen
Jan 6, 2011·FEMS Microbiology Reviews·Manish SadaranganiScott D Gray-Owen
Mar 17, 2015·Vaccine·Heleen KraanJean-Pierre Amorij
Apr 23, 2016·Scientific Reports·Nancy L PriceMario F Feldman
Mar 3, 2018·Vaccines·Pumtiwitt C McCarthyLaleh Sheikhi Moghaddam
Sep 16, 2021·Expert Review of Vaccines·Myron ChristodoulidesJohn E Heckels

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.